Patent: 10,233,257

« Back to Dashboard

Summary for Patent: 10,233,257

Title:	Methods for preparing antibody-drug conjugates
Abstract:	This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
Inventor(s):	Brenda A. Kellogg, Rajeeva Singh, Ravi V. J. Chari
Assignee:	Immunogen Inc
Application Number:	US15/694,164
Patent Claims:	see list of patent claims

Details for Patent 10,233,257

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	July 13, 2017		2037-09-01
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	January 28, 2019		2037-09-01
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	September 11, 2024		2037-09-01
Janssen Biotech, Inc.	TREMFYA	guselkumab	Injection	761061	March 25, 2025		2037-09-01

International Patent Family for US Patent 10,233,257

Country	Patent Number	Estimated Expiration
Australia	2010256659
Brazil	PI1010620
Canada	2761959
China	102448500
China	104984360